Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novogene CoSHSE:688315 +4.00%86 Return-on-Tangible-Equity is 4.49% as of Mar. 2026, which is 53% below its 10-year median of 9.56. GuruFocus rates SHSE:688315 with a GF Score™ of 86/100 and a GF Value™ of ¥16.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,200 Biotechnology companies, Novogene Co ranks better than 83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Novogene Co's annualized net income for the quarter that ended in Mar. 2026 was ¥118 Mil. Novogene Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥2,622 Mil. Therefore, Novogene Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.49%.
The historical rank and industry rank for Novogene Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688315'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.41 Med: 9.56 Max: 15.9
Current: 6.34
During the past 11 years, Novogene Co's highest Return-on-Tangible-Equity was 15.90%. The lowest was 3.41%. And the median was 9.56%.
SHSE:688315's Return-on-Tangible-Equity is ranked better than 83% of 1200
companies
in the Biotechnology industry
Industry Median: -42.53
vs SHSE:688315: 6.34
Novogene Co (SHSE:688315) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Novogene Co Return-on-Tangible-Equity Related Terms
Novogene Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Novogene Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688315 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Novogene Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novogene Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novogene Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Novogene Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.49% mean?
Novogene Co (SHSE:688315) has a Return-on-Tangible-Equity of 4.49% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Novogene Co and its competitors. This is 53% below median its historical median of 9.56. Over the past decade, Novogene Co's Return-on-Tangible-Equity has ranged from 3.41 to 15.90. According to the industry distribution chart, Novogene Co ranks #204 out of 1200 companies in the Biotechnology industry, placing it in the top 17%.
Is Novogene Co's Return-on-Tangible-Equity too high?
Novogene Co's current Return-on-Tangible-Equity of 4.49% is 53% below median its 10-year median of 9.56. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 15.90. Based on the distribution chart, Novogene Co ranks #204 out of 1200 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Novogene Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novogene Co ranks #204 out of 1200 companies for Return-on-Tangible-Equity. This places Novogene Co in the top 17% of its industry — outperforming the majority of peers. Historically, Novogene Co's own Return-on-Tangible-Equity has ranged from 3.41 to 15.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Novogene Co and its competitors. Novogene Co's current Return-on-Tangible-Equity is 4.49%, which is 53% below median its own 10-year median of 9.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥16.03, compared to a current price of ¥13.77 — trading 14.1% below its estimated fair value. The current Return-on-Tangible-Equity is 4.49%, which is 53% below median its 10-year median of 9.56. Novogene Co's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current Return-on-Tangible-Equity is 4.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novogene Co (SHSE:688315) Overvalued in 2026?
Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued.
The current stock price of ¥13.77 is trading 14.1% below its estimated GF Value™ of ¥16.03.
GuruFocus considers Novogene Co to be Modestly Undervalued.
Key valuation signals for SHSE:688315:
Return-on-Tangible-Equity: 4.49% (53% below median its 10-year median of 9.56)
GF Value™: ¥16.03 vs. price of ¥13.77 (14.1% below fair value)
No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
86GF Score
Get the complete analysis for SHSE:688315
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688315 has been successfully added to your 
